Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Russell

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Leukemia|July 31, 2020
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Mayo Clinic Proceedings|February 17, 2019
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified TypingEli Muchtar, Morie A Gertz, Robert A Kyle, et al.
Leukemia|October 27, 2021
Mortality trends in multiple myeloma after the introduction of novel therapies in the United StatesMoritz Binder, Bharat Nandakumar, S Vincent Rajkumar, et al.
Leukemia|November 24, 2019
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care CenterLaura A Evans, Ronald Go, Rahma Warsame, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Leukemia|July 31, 2020
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Mayo Clinic Proceedings|February 17, 2019
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified TypingEli Muchtar, Morie A Gertz, Robert A Kyle, et al.
Leukemia|October 27, 2021
Mortality trends in multiple myeloma after the introduction of novel therapies in the United StatesMoritz Binder, Bharat Nandakumar, S Vincent Rajkumar, et al.
Leukemia|November 24, 2019
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care CenterLaura A Evans, Ronald Go, Rahma Warsame, et al.
British Journal of Haematology|July 13, 2019
Ten-year survivors in AL amyloidosis: characteristics and treatment patternEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
Pageof 10